Indian Bar Association Takes Legal Action Against WHO Chief Scientist For ‘Spreading Disinformation’ Regarding COVID-19

Written by K. Walker on June 9, 2021

Become a Clash Insider!

Big Tech is clamping down on conservative media big time. Don’t let Big Tech pre-chew your news. Sign up for our free email newsletter, and we’ll make sure to keep you in the loop.

The Indian Bar Association is seeking to “prevent further damage” the doctor caused by allegedly ignoring studies and “deliberately” suppressing data regarding the effectiveness of therapeutics against the novel coronavirus.

The Indian Bar Association (IBA) has taken legal action against the World Health Organization’s Chief Scientist, Dr. Soumya Swaminathan, for “misguiding the people of India in order to fulfill her agenda” because she advised against the use of Ivermectin despite clinical trials that show that it is effective at preventing and treating the Wuhan virus.

The legal notice requires Dr. Swaminathan to provide answers on a number of key points, and if the response is unclear, it “reserves the right to initiate prosecution under sections of the Indian Penal Code and Disaster Management Act, 2005.”

The association (IBA) served a legal notice (pdf) on Swaminathan on May 25, claiming that she was “spreading disinformation and misguiding the people of India, in order to fulfill her agenda” and sought to prevent her from “causing further damage.”

They further stated that Swaminathan, in her statements against the use of ivermectin, ignored research and clinical trials from two organizations—the Front Line COVID-19 Critical Care (FLCCC) Alliance and the British Ivermectin Recommendation Development (BIRD)—who have presented solid data showing ivermectin prevents and treats COVID-19.

“Dr. Soumya Swaminathan has ignored these studies/reports and has deliberately suppressed the data regarding effectiveness of the drug Ivermectin, with an intent to dissuade the people of India from using Ivermectin,” the IBA said in a statement (pdf).

In a May 10 Twitter post that was deleted after Swaminathan received the notice, she wrote, “Safety and efficacy are important when using any drug for a new indication. WHO recommends against the use of ivermectin for COVID-19 except within clinical trials.”

According to ivmmeta.com, a real-time meta-analysis of 57 clinical trials involving more than 18,000 patients, Ivermectin has been shown to impair the virus’s ability to replicate thereby preventing severe illness and hospitalization.

In an interview on March 6, Dr. Tess Lawrie said that since the drug was first given to humans in 1987, there have only been 4,600 adverse events and 16 deaths reported on the pharmacovigilance database.

Dr. Pierre Kory, President and Chief Medical Officer of the FLCCC Alliance, said in an interview on June 1, “There are forces that are seeking to make sure that ivermectin is not accepted widely as an effective therapy.”

Merck, the pharmaceutical company that developed Ivermectin in the 1980s and held the patent until 1996 issued a statement saying that they “do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information.”

But don’t worry! They’re working on a new drug to do what Ivermectin has been shown to do. They’ll just have a patent on it this time.

Merck, in collaboration with Ridgeback Biotherapeutics, is conducting a Phase 3 trial of the investigational anti-viral drug molnupiravir, which the company claims has shown to reduce infectious viruses quicker in COVID-19 outpatients. But unlike ivermectin, molnupiravir demonstrated no clinical benefit in hospitalized patients.

The trial is expected to complete later this October, and Merck said it’ll apply for an emergency authorization use for the drug if the results are favorable.

It’s almost like Big Pharma doesn’t want to give up the Global Pandemic Cash Cow to use cheap, widely available, and remarkably safe medications that no longer have patents in favor of experimental drugs that they could make money on. Gee, I can’t imagine why they’d want to do that. 

The FDA has not approved the use of Ivermectin for the prevention or treatment of coronavirus and has advised against its use for that purpose. The NIH updated its guidelines in February and is going to conduct a controlled study on Ivermectin. The WHO has advised against its use for coronavirus except in clinical trials.

In April, the NIH announced it would fund a large randomized, controlled study of seven repurposed drugs to treat mild to moderate COVID-19 patients. The research agency said it will begin enrolling for its Phase 3 trial on ivermectin this month.

“Trial enrollment is expected to open this month, and the trial is expected to run for up to two years,” an NIH spokesperson told The Epoch Times in an email.

The WHO, in its Living Guideline, has advised against the use of ivermectin except in a clinical setting, citing inconclusive data similar to both the FDA and the NIH.

“The current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive,” the WHO said in a statement. “Until more data is available, WHO recommends that the drug only be used within clinical trials.”

Dr. Swaminathan posted her tweet after the health minister for the Indian state of Goa announced that every resident 18 and older would be given ivermectin regardless of their COVID-19 status in order to prevent the spread of the virus. The small state of Goa fared better than other Indian districts in the brutal second wave of the pandemic.

According to data by the Johns Hopkins University Center for Systems Science and Engineering, Tamil Nadu saw 20,421 new cases and 434 deaths on June 6, while Goa recorded 403 new cases and 16 deaths and Uttar Pradesh reported 1,037 cases and 85 deaths.

Uttar Pradesh, one of the most populous states in India with more than 200 million people, has been handing out free medical kits containing seven days’ worth of medication, one of which is ivermectin, for COVID-19 positive patients under home isolation.

Source: Epoch Times

Dr. Swaminathan is scheduled to give the keynote address at this year’s UCL-Lancet Lecture. It’s titled, “Lessons from the Pandemic for Science and Public Health.”

That could be a very awkward speech if she’s being sued by the Indian Bar Association for disinformation on effective therapeutics for the coronavirus that may have cost tens or even hundreds of thousands of lives all over the world.

Related:

 

You Might Like
ClashDaily's Associate Editor since August 2016. Self-described political junkie, anti-Third Wave Feminist, and a nightmare to the 'intersectional' crowd. Mrs. Walker has taken a stand against 'white privilege' education in public schools. She's also an amateur Playwright, former Drama teacher, and staunch defender of the Oxford comma. Follow her humble musings on Twitter: @TheMrsKnowItAll